Mylan N.V. (NASDAQ:MYL) Earning Somewhat Positive Media Coverage, Analysis Finds
News articles about Mylan N.V. (NASDAQ:MYL) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mylan N.V. earned a news impact score of 0.03 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.2092207565303 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Mylan N.V. (MYL) Stock Rating Reaffirmed by BMO Capital Markets (americanbankingnews.com)
- Mylan N.V. (NASDAQ:MYL) Receives “Buy” Rating from UBS AG (americanbankingnews.com)
- Mylan NV (MYL) Stock Hit by Forecast Cut – Investorplace.com (investorplace.com)
- Generic Drug Price Slump’s Latest Victim: Mylan Profit Goal – Bloomberg (bloomberg.com)
- Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View – Nasdaq (nasdaq.com)
Mylan N.V. (MYL) traded up 0.65% on Thursday, hitting $32.29. 12,327,439 shares of the stock traded hands. The stock has a 50-day moving average price of $37.74 and a 200 day moving average price of $39.09. Mylan N.V. has a 12-month low of $29.58 and a 12-month high of $49.42. The stock has a market cap of $17.31 billion, a P/E ratio of 32.26 and a beta of 1.27. Mylan N.V. also saw unusually large options trading activity on Monday. Investors acquired 9,410 call options on the company. This is an increase of 250% compared to the average daily volume of 2,688 call options.
Mylan N.V. (NASDAQ:MYL) last announced its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.18 by $0.08. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The company had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3 billion. During the same period in the prior year, the firm posted $1.16 earnings per share. The company’s revenue was up 15.7% on a year-over-year basis. On average, equities analysts expect that Mylan N.V. will post $4.86 EPS for the current fiscal year.
Several equities research analysts recently weighed in on the stock. Barclays PLC upgraded shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $47.00 to $50.00 in a research note on Monday, May 22nd. Royal Bank Of Canada reiterated a “sector perform” rating and set a $46.00 price objective (down previously from $48.00) on shares of Mylan N.V. in a research note on Monday, April 17th. BMO Capital Markets assumed coverage on shares of Mylan N.V. in a research note on Monday, May 1st. They set an “outperform” rating and a $50.00 price objective on the stock. Wells Fargo & Company reiterated a “market perform” rating and set a $40.00 price objective on shares of Mylan N.V. in a research note on Friday, April 14th. Finally, Cantor Fitzgerald assumed coverage on shares of Mylan N.V. in a research note on Friday, June 16th. They set a “neutral” rating and a $41.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $47.83.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/mylan-n-v-nasdaqmyl-earning-somewhat-positive-media-coverage-analysis-finds.html.
In other Mylan N.V. news, insider Anthony Mauro sold 10,000 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the transaction, the insider now directly owns 140,653 shares of the company’s stock, valued at $5,626,120. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Rajiv Malik sold 25,000 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the president now directly owns 799,855 shares of the company’s stock, valued at $31,994,200. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.